Search 

Distributer for pharmaceutical products

Enosi's lead programs involve novel inhibitors of TNF (tumor necrosis factor), which include severe inflammation associated with viral infections, autoimmune disease, fibrotic diseases, Alzheimer’s, cancer and other diseases. The current TNF inhibitors have important “Black Box” warnings for opportunistic infections, cancer, and cardiovascular events, like stroke. Enosi believes our compounds in development will avoid these limitations of current drugs, be more effective, and will allow expansion into many indications/markets that cannot be approached at the present time by current TNF inhibitors because of their side-effects.

ExoProTher Medical is an Israeli pre-clinical stage company developing a novel biotherapy for cancer treatment, relevant to all cancers with p53 mutation or inactivation - more than 60% of human cancers. Our technology is unique and disruptive and is fully owned by the company.

The company has been funded by private investors. We are currently working on shaping our next funding round.

At FJS Biopharmaceutical Inc., we combine technological innovation with world class process excellence. These enable our customers to deliver their discoveries. In our extensive contract development services portfolio we use advanced technologies to quickly and efficiently deliver products such as monoclonal antibodies, complex proteins and recombinant proteins.

Changes in the global marketplace are quickly altering the demands on biopharmaceutical manufacturing facilities. we have changed to Continuous Manufacturing Processes design that is cost-effective, flexible and responsive to a diversified product line. Continuous manufacturing processes offers a number of advantages:
1. More agile and flexible, and can therefore respond more rapidly to changes in supply or demand.
2. Reducing or eliminating scale-up bottlenecks could also help to accelerate the path to market for breakthrough
pharmaceuticals.
3. More efficient, reliable and cost-effective than traditional batch methods, resulting in significant cost savings down the line.
4. Producing smaller environmental footprint and reduce the risk of product quality failures compared to batch systems.
5. Supports a systematic, scientific and risk-based approach to pharmaceutical development. Development of a robust
process relies on utilizing the acquired product and process understanding to identify sources of variation to product quality
and to design appropriate control strategies to address these risk areas.
6. provides an opportunity to utilize this enhanced product and process understanding to adopt advanced manufacturing
controls and to produce uniformly high-quality products with reduced waste resulting from the generation of out-of-
specification material.

We are a preferred global partner to the Biopharmaceutical, biotech and specialty ingredients markets. Our solutions improve life quality by preventing illness, enabling healthier lifestyles and supporting a safe environment.

Real-time Data Aggregation and analytics in real-time

We support companies gather information and analyze information in real-time speed access to insight facts and evidence into suppliers, vendors. partners and customers

Focus-X is a preclinical stage biotech company committed to the discovery and development of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.

GattaCo is a Southern California start-up that has developed disruptive new technologies and products solving billion dollar bottlenecks in healthcare. These include its A-PON™ and Pediatric mini-PON™ Kits, which are self-contained, fully-automatic and disposable centrifuge replacement tools. The PON devices are used to extract a precise volume of antibody-rich plasma from a few drops of finger-stick capillary blood so that the plasma can be dispensed into a rapid diagnostic testing platform, such as a rapid COVID-19 antibody test, or into a tube for shipping liquid plasma to a clinical lab for analysis. The mini-PON device eliminates the need for a venipuncture for pediatric blood testing. The availability of liquid plasma for clinical lab processing, collected and processed remotely, greatly simplifies lab workflow compared to dried blood sample processing and provides a more consistent and stable sample for high-sensitivity and high-throughput serological testing. When used in conjunction with rapid antibody tests, the PON devices can provide more consistent, higher-sensitivity and quantitative results compared to the same volume of whole blood, and may allow clinically significant rapid tests to be performed in Point of Care settings.

There is a high unmet need for central nervous system (CNS) diseases in the growing aging population. Genervon is bringing GM6, a new clinical-stage drug asset, to regulatory approval and commercialization in China for CNS diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. Most clinical trials for drugs developed through the traditional single-target drug approach have failed to treat the complex neurological disorders that involve multiple interrelated pathways. GM6 is neither an antibody nor a single-target agonist or antagonist. It is a pleiotropic regulator which simultaneously regulates multiple pathological pathways. Genervon has validated GM6’s target engagement of multiple targets and druggability. GM6 has been de-risked for toxicity in animal studies and safety in three clinical trials. IND documents filed with the FDA can be used to support regulatory filing in China for clinical trials. Genervon is interested to partner through licensing or merger and acquisition. 
Genervon Biopharmaceuticals discovered an endogenous embryonic-stage regulator, Motoneuronotrophic Factor (MNTF), and developed from it the pleiotropic drug GM6. Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases related to aging. GM6 simultaneously modulates multiple biological mechanisms (MOA) in the CNS and immune system to increase neurogenesis and lower inflammation. The MOAs include oxidative Stress, protein aggregation, kinase dysfunction, cholinergic signaling, extracellular matrix stability, and intrinsic apoptosis. GM6 reduces Beta Amyloid and phosphorylated tau in AD, reduces SOD1 in ALS, and reduces inflammation in animal models. GM6 passes through the blood-brain barrier and has good drug-like properties. GM6 has been studied in a Phase 1 and two Phase 2A trials and was shown to be safe and tolerable with positive clinical outcomes and favorable shifts in biomarkers SOD1, Tau and TDP43 in patients. A complete CMC package is ready for technology transfer.

A clinical-stage pharma company with a P2B asset targeted
for multiple psychiatric disorders with unmetmedical needs.
The parent company, Generys Therapeutics Corp.
headquartered in Rep. of Korea is a controlled foreign
company (US IRS code).